Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis

(2014) R. W. Stidham et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of infliximab in treating patients with ulcerative colitis: Experiences from a single medical center in southern China

(2014) You Lian Zhou et al.   Journal of Digestive Diseases

Adalimumab in active ulcerative colitis: A “real-life” observational study

(2013) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Mitochondrial Gene Polymorphisms That Protect Mice From Colitis

(2013) Florian Bär et al.   GASTROENTEROLOGY

Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study

(2013) Nabeel Khan et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience

(2013) Stephen J Halpin   WORLD JOURNAL OF GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort

(2010) N. Gies et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

(2009) X Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

(2009) Waqqas Afif et al.   INFLAMMATORY BOWEL DISEASES

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis